Piper Sandler sets a price target of $142 for NASDAQ:ABVX, indicating a potential increase of 27.95%.The "Strong Buy" rating is driven by positive phase 3 ABTECT induction data for obefazimod, highlighting its potential in the ulcerative colitis therapy market.Abivax plans significant milestones in 2026, including filing for New Drug Application (NDA) and Marketing Authorization Application (MAA) if trials remain positive.Abivax SA (NASDAQ:ABVX) is a biopharmaceutical company focused on developing therapies ...